Alkermes ENLIGHTEN Hints At Efficacy Benefit But Weight Profile Still In Balance

 
• By Alexandra Shimmings

The first Phase III trial results for Alkermes' combination product for schizophrenia ALKS 3831 show hints of added benefit over olanzapine alone but no benefit yet on weight gain, the product's raison d'être. Analysts are hoping upcoming longer-term data will produce the goods.

Zen stones
ENLIGHTEN Benefits Weighed In The Balance • Source: Shutterstock

More from Clinical Trials

More from R&D